Bio clinical biostatistics multiplicity graphical

Version Compatibility

Reference examples tested with: R gMCP 0.8.16+, graphicalMCP 0.2+, gatekeeping, multcomp, multxpert; Python statsmodels 0.14+ for basic FDR/FWER methods.

Before using code patterns, verify installed versions match. If versions differ:

• R: packageVersion('<pkg>') then ?function_name
• Python: pip show <package> then help(module.function)

If code throws ImportError, AttributeError, or TypeError, introspect the installed package and adapt the example to match the actual API rather than retrying.

Multiplicity Control for Confirmatory Trials

"Design the multiplicity strategy for my trial" -> Specify a closed-testing procedure (graphical, gatekeeping, hierarchical, or step-down Bonferroni-Holm) that controls family-wise error rate at the trial-wide level across primary endpoints, key secondary endpoints, and subgroup analyses, with provable strong FWER control.

The Foundational Theorem -- Closed Testing Is Necessary

Marcus, Peritz & Gabriel 1976 Biometrika 63:655: a hypothesis H_I (I ⊆ {1,...,m}) is rejected iff every intersection hypothesis ∩_{J⊇I} H_J is rejected by a valid α-level local test. Strong FWER control holds for ANY choice of local tests.

Goeman, Hemerik & Solari 2021 Ann Stat 49:1218 tightens this: closed testing is not merely sufficient — it is necessary for admissibility under FDP/FWER/k-FWER. Every admissible multiplicity procedure is equivalent to some closed test. Graphical procedures, gatekeepers, Hommel, fixed-sequence, fallback — all are closed tests in disguise.

FWER vs FDR philosophical divide:

• FWER: P(any false positive among m tests) — regulatory standard for confirmatory inference (agency wants to bound per-trial false-positive rate)
• FDR: Expected proportion of false discoveries among rejections — exploratory standard (genomics, fMRI, biomarker screens) where many true positives expected

Confirmatory clinical trials use FWER essentially universally.

Algorithmic Taxonomy

Procedure	Type	FWER control	Power profile	Use case
Bonferroni	Single-step	Yes, any dependence	Conservative; loses 30-50% power vs Hommel under positive dependence	Very small m; worst-case dependence
Holm 1979	Step-down	Yes, any dependence	Better than Bonferroni; uniformly dominates	Default for any dependence pattern
Hochberg 1988	Step-up	Yes under PRDS (Sarkar 1998)	Better than Holm under PRDS	Positive correlation; verify PRDS
Hommel 1988	Step-up via closed tests	Yes under PRDS	Uniformly dominates Hochberg by 1-3%	Whenever Hochberg is valid
Fixed-sequence (hierarchical)	Sequential	Yes, any dependence	Full alpha for first; subsequent zero if any fail	When clear priority ordering; "key secondary" labelling
Parallel gatekeeping (Dmitrienko 2003)	Multi-family	Yes	Family-by-family; secondary tested if any primary rejects	Primary family + secondary family
Serial gatekeeping	Sequential families	Yes	Strict: family k tested only if ALL of family k-1 reject	Co-primary + secondary tiers
Mixed gatekeeping (Dmitrienko-Tamhane 2008)	Combination	Yes	Combines closed-testing local procedures across families	Complex hierarchies
Graphical procedures (Bretz-Maurer 2009)	Closed-test as directed graph	Yes by construction	Flexible; allocate alpha to hypotheses via graph weights	Modern standard for confirmatory SAPs
Graphical + Simes/parametric (Bretz et al 2011)	Closed-test with non-Bonferroni local tests	Yes when Simes valid	Gains power under correlation	Complex co-primary + key secondary + subgroup hierarchies
Maurer-Bretz 2013 entangled graphs	Memory-augmented graphs	Yes by construction	Alpha propagation depends on origin	Parent-descendant constraints
Benjamini-Hochberg 1995	FDR	FDR controlled at level q	Higher power than FWER	Exploratory only; NOT for confirmatory regulatory

Postdoc reading list:

• Marcus R, Peritz E, Gabriel KR 1976 Biometrika 63:655 (closed testing — the foundation)
• Goeman JJ, Hemerik J, Solari A 2021 Ann Stat 49:1218 (closed testing necessary for admissibility)
• Holm S 1979 Scand J Stat 6:65 (step-down Bonferroni)
• Hochberg Y 1988 Biometrika 75:800 (step-up Simes)
• Hommel G 1988 Biometrika 75:383 (closed Simes; dominates Hochberg)
• Sarkar SK 1998/2008 Ann Stat (PRDS for Hochberg validity)
• Bretz F, Maurer W, Brannath W, Posch M 2009 Stat Med 28:586 (graphical procedures — foundational paper)
• Bretz F, Posch M, Glimm E, Klinglmueller F, Maurer W, Rohmeyer K 2011 Biom J 53:894 (Simes/parametric extensions)
• Maurer W, Bretz F 2013 Stat Med 32:1739 (entangled graphs / memory)
• Dmitrienko A, Offen WW, Westfall PH 2003 Stat Med 22:2387 (parallel gatekeeping)
• Dmitrienko A, Tamhane AC, Wiens B 2008 Biom J (mixed/multistage gatekeeping)
• FDA 2022 Multiple Endpoints in Clinical Trials Final Guidance (October 2022)
• Pocock SJ, Ariti CA, Collier TJ, Wang D 2012 Eur Heart J (win-ratio)

Decision Tree by Scenario

Scenario	Recommended procedure	Why
2 co-primary endpoints (both must succeed)	No alpha split needed; per-endpoint alpha-level test; cite FDA 2022	Co-primary doesn't split alpha; inflates n via joint power
2 multiple primary endpoints (any-wins)	Graphical procedure or Holm with weights	Alpha must be allocated; graphical is flexible
1 primary + 2 key secondary endpoints	Hierarchical (serial gatekeeping) OR graphical with alpha propagation	Modern SAPs favour graphical
1 primary + 3 secondary + 4 subgroup analyses	Graphical procedure via gMCP with pre-specified weights	Complex hierarchies benefit from graph visualisation
Primary endpoint + tipping-point sensitivity	No multiplicity adjustment needed for sensitivity	Sensitivity is "what if" not "another claim"
Many exploratory biomarker subgroups	Benjamini-Hochberg FDR	Exploratory; not for label claims
Win-ratio composite (cardiology)	Single test; no multiplicity	Composite captures multiple events in single hierarchy
Subgroup analysis (pre-specified)	Graphical alpha allocation; small budget (≤20% by convention); see Dane 2019 for subgroup discipline	Confirmatory subgroup discovery requires explicit allocation
Adaptive trial with treatment arm dropping	Combination tests (Bauer-Köhne 1994) + closed testing	See clinical-biostatistics/adaptive-designs
Group-sequential with multiple endpoints	gsDesign or rpact with multivariate alpha spending	Hierarchical alpha across both time and endpoints

Bretz-Maurer Graphical Procedures -- The Modern Standard

The Bretz-Maurer-Brannath-Posch 2009 Stat Med 28:586 framework recast weighted Bonferroni-Holm closed tests as directed weighted graphs:

• Vertices = elementary null hypotheses with local weights summing to 1
• Directed edges = alpha-propagation rule (when a hypothesis is rejected, its weight redistributes to descendants per edge weights)
• The graph IS the procedure: a single visual fully specifies a closed-test procedure across primary, key secondary, and subgroup hierarchies

gMCP R package

library(gMCP)

# Construct a graph for primary + 2 key secondary endpoints
# Primary endpoint at full alpha; if rejected, alpha propagates equally to secondaries
hypotheses <- c('Primary', 'Sec1', 'Sec2')
weights <- c(1, 0, 0)  # initial alpha all on primary
# Transition matrix: rows = source, columns = target
# When Primary rejects, weight 0.5 goes to each secondary; when Sec1/Sec2 rejects, alpha returns
transitions <- matrix(c(
    0,    0.5,  0.5,
    0,    0,    1,
    0,    1,    0
), nrow = 3, byrow = TRUE, dimnames = list(hypotheses, hypotheses))

graph <- graphMCP(m = transitions, weights = weights, hnames = hypotheses)
# Note: in current gMCP, the graph constructor is `graphMCP(m=, weights=, hnames=)`;
# `matrix2graph()` appeared in older tutorials and is not the canonical exported API
# -- verify with `?graphMCP` / `?gMCP` in the installed gMCP release before scripting.
# Set p-values from the trial
p_vals <- c(Primary = 0.018, Sec1 = 0.042, Sec2 = 0.038)

# Run the graphical procedure at alpha = 0.025
result <- gMCP(graph, pvalues = p_vals, alpha = 0.025)
print(result)
# Hierarchical rejection: Primary rejects -> alpha propagates to secondaries -> ...

Standard SAP graph patterns

Pattern	Graph topology	Use
Pure hierarchical (fixed sequence)	H1 -> H2 -> H3 with weight 1 on each transition	Strict ordering
Holm graph (equal weights)	Each Hi -> Hj with weight 1/(m-1)	No priority ordering
Primary + secondaries	Primary -> Sec1 (0.5), Sec2 (0.5); Sec1 ↔ Sec2 (1)	Pivotal labeling claims
Co-primary chain	H1 -> H2 with full weight if BOTH H1a, H1b reject	Co-primary + secondary
Subgroup branch	Primary -> Subgroup_OS (0.2), Sec1 (0.4), Sec2 (0.4)	Discovery subgroup with budget

Bretz et al 2011 -- Simes and parametric extensions

When endpoints are positively correlated, replace the Bonferroni-based intersection test with Simes (for positive dependence) or parametric (using known correlation):

library(gMCP)
# Use Simes-based local tests at each intersection
result_simes <- gMCP(graph, pvalues = p_vals, alpha = 0.025, test = 'Simes')
# Or parametric with estimated correlation matrix
result_param <- gMCP(graph, pvalues = p_vals, alpha = 0.025, corr = correlation_matrix)

Maurer-Bretz 2013 entangled graphs

Entangled graphs add memory: the alpha propagation can depend on the origin of the alpha. This allows parent-descendant constraints that a single non-entangled graph cannot express. Example: secondary endpoint Sec1 receives alpha only from Primary, never from Sec2.

Postdoc argument: purists argue memory makes the procedure non-coherent in Gabriel's sense; Glimm/Maurer/Bretz argue it matches real-world inferential intent.

Gabriel coherence in plain terms: a coherent procedure rejects a hypothesis H consistently regardless of which superset of H is being tested. Non-entangled graphs are coherent: if H1 is rejected via path A, it would also be rejected via path B. Entangled (memory-bearing) graphs sacrifice coherence: the same H may be rejected when alpha arrives from one parent but not from another, because the propagation history changes the available alpha. The trade-off is operational power -- entangled graphs can encode "secondary X is meaningful only if primary Y rejects, not if primary Z rejects" inferential intent that flat coherent procedures cannot express. Choose based on whether the SAP needs path-dependent priority.

Gatekeeping Procedures

Serial gatekeeping (hierarchical)

Test H1 at full alpha; only if it rejects, test H2 at full alpha; etc. Maximises power for H1 but H_k becomes inferentially worthless once any H_j (j<k) fails.

# Hierarchical / serial: just a chain graph in gMCP
hyp <- c('H1', 'H2', 'H3', 'H4')
weights <- c(1, 0, 0, 0)
trans <- matrix(c(0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0),
                 nrow=4, dimnames=list(hyp, hyp))
graph <- graphMCP(m = trans, weights = weights, hnames = hyp)

Pre-specification of order is critical — based on clinical importance, NOT expected effect size. Ordering by expected effect is data-driven and inflates Type-I.

Parallel gatekeeping (Dmitrienko 2003)

Secondary family is tested only if at least one primary rejects. Bonferroni-based parallel gatekeeper has stepwise representation (Guilbaud 2007 Biom J 49:917).

Mixed / multistage (Dmitrienko-Tamhane 2008)

Permits using any closed-testing local procedure (e.g., Holm in family 1, Hommel in family 2) and combining via closure principle. R gMCP::generalMixGatekeeping or Mediana/MultXpert packages.

Postdoc tradeoff: parallel gatekeeping power loss vs collapsing endpoints into a composite (which avoids multiplicity but dilutes effect if components move in opposite directions); whether tree gatekeeping (Dmitrienko et al 2008 Stat Med 27:3446) over-engineers vs equivalent graphical procedure.

Hochberg vs Hommel vs Holm

Holm 1979 — step-down rejective Bonferroni; FWER controlled under any joint dependence. Conservative but robust.

Hochberg 1988 — step-up using ordered Simes critical values; needs Simes inequality which requires PRDS (Sarkar 1998, 2008). Under PRDS, Hochberg uniformly dominates Holm.

Hommel 1988 — also Simes-based but uses closed-testing tableau directly (not step-up shortcut). Uniformly more powerful than Hochberg (typically 1-3% gain).

When Hochberg fails (anti-conservative)

Hochberg becomes Type-I-inflated under negative dependence — relevant when comparing endpoints mathematically constrained to move in opposite directions (LDL-C and HDL-C; complementary efficacy and safety endpoints).

Sarkar critique: when PRDS cannot be proven, fall back to Holm. The lost power is the price of robustness.

# Python: statsmodels supports Holm, Hochberg, Hommel
from statsmodels.stats.multitest import multipletests

p_vals = [0.018, 0.042, 0.038, 0.015]
for method in ['holm', 'hochberg', 'hommel', 'bonferroni']:
    reject, adj_p, _, _ = multipletests(p_vals, alpha=0.05, method=method)
    print(f'{method}: reject={reject}, adjusted={adj_p}')

FDA Multiple Endpoints Final Guidance (October 2022)

Federal Register 2022-22882 finalises 2017 draft. Key changes vs draft:

• Explicit recognition of newer methods including win-ratio (Pocock 2012 Eur Heart J) and weighted composites
• Clearer language that "key secondary" endpoints are those for which sponsor wishes to make label claims and which must be in a Type-I-error-controlled hierarchy
• Appendix with worked graphical-procedure examples

Categories

Category	Approach	Note
Composite	Single test; no multiplicity	Win-ratio, DOOR/RADAR, time-to-first-event
Co-primary (all-win)	Each at full alpha; n inflated for joint power	Power = product of marginals
Multiple primary (any-wins)	Alpha must be split (Bonferroni or graphical)	More n required than co-primary if effects similar
Primary + key secondary	Hierarchical or graphical	Modern preference: graphical for flexibility

Winner's bias warning: when post-hoc-selected endpoints are emphasised, bias-corrected effect estimates are recommended (same selection-bias issue as adaptive design).

The "Almighty Primary Endpoint" Critique

Dmitrienko-D'Agostino 2017 Stat Med 36:4423 editorial surveys progress in trial-multiplicity methodology. A recurring theme motivating that work: insisting on a single primary endpoint can lose power when a therapy has broad multi-domain benefit (heart failure drugs with effects on mortality, hospitalisation, symptoms, biomarkers) -- motivating composite endpoints, the win ratio, or multiple primary endpoints with explicit alpha allocation.

Win-ratio (Pocock-Ariti-Collier-Wang 2012) and hierarchical composite (DOOR/RADAR, Evans 2015) are responses — they preserve a single inferential test while letting multiple endpoints contribute.

FDA counter-position (Hung, O'Neill, Wang): without a designated primary, sponsors and regulators negotiate over secondary endpoints post hoc, destroying inferential meaning. Hence the FDA 2022 guidance reaffirms key-secondary hierarchies.

Per-Method Failure Modes

Hochberg under negative dependence

• Trigger: Endpoints constrained to move in opposite directions (LDL vs HDL; efficacy vs harm).
• Mechanism: Hochberg's PRDS assumption fails; Simes inequality doesn't hold; Type-I inflated.
• Symptom: Replication with Holm finds non-significant where Hochberg rejected.
• Fix: Switch to Holm (no PRDS assumption); cite Sarkar 1998.

Fixed-sequence with wrong ordering

• Trigger: Ordering by expected effect size rather than clinical priority.
• Mechanism: Data-driven ordering inflates Type-I.
• Symptom: Reviewer asks for pre-specified ordering rationale.
• Fix: Pre-specify order by clinical priority in SAP; document rationale.

Graphical procedure without pre-specified weights

• Trigger: Weights chosen at analysis time to favour observed results.
• Mechanism: Equivalent to post-hoc multiplicity tuning; inflates Type-I.
• Symptom: Multiple "what if" graph variants in CSR.
• Fix: Pre-specify graph and weights in SAP; document at protocol design.

Bonferroni when graph would gain power

• Trigger: Default conservative choice when no thought put into structure.
• Mechanism: Loses 30-50% power vs Hommel/graphical when m ~ 10 correlated tests.
• Symptom: Underpowered trial reaches non-significance where graphical procedure would.
• Fix: Design a proper graph in gMCP; cite Bretz-Maurer 2009.

FDR used for confirmatory primary

• Trigger: SAP specifies BH-FDR for primary multiplicity.
• Mechanism: FDR controls expected proportion of false discoveries, not P(any false positive).
• Symptom: Regulatory reviewer rejects as non-confirmatory.
• Fix: FWER (graphical, Holm, Hochberg, Hommel) for confirmatory; FDR for exploratory only.

Subgroup analyses claimed without multiplicity

• Trigger: Trial reports 10 subgroups with one significant at α=0.05.
• Mechanism: ~40% probability of at least one false positive under global null.
• Symptom: Cherry-picked subgroup claim in submission.
• Fix: Pre-specified graphical alpha allocation OR explicit hypothesis-generating label; cite EMA 2019 subgroup guideline.

Win-ratio reported without hierarchical priority

• Trigger: Win-ratio composite with unspecified component priority.
• Mechanism: Component prioritisation drives the result; arbitrary choice = data-dependent answer.
• Symptom: Two analysts get different results from same data depending on hierarchy.
• Fix: Pre-specify hierarchy in SAP; sensitivity over alternative hierarchies.

Quantitative Thresholds

Threshold	Source	Rationale
FWER for confirmatory; FDR for exploratory	ICH E9; FDA 2022 Multiple Endpoints	Regulatory standard universally
Bonferroni: ~10 tests -> 30-50% power loss	Sarkar 1998 PRDS	Conservative under positive dependence
PRDS required for Hochberg validity	Sarkar 2008 Ann Stat	Otherwise Type-I inflated; fall back to Holm
Subgroup α budget <=20% of total (convention)	Dane 2019 EFSPI white paper (subgroup discipline)	Discipline against subgroup fishing
Key secondary requires hierarchy in SAP	FDA 2022 Final	Labeling claims need Type-I-controlled test
Composite avoids multiplicity but dilutes effect	Pocock 2012 Eur Heart J	Win-ratio captures heterogeneity in single test

Common Errors

Error / symptom	Cause	Solution
Hochberg applied to negatively-dependent endpoints	PRDS not checked	Switch to Holm (cite Sarkar 1998)
Fixed-sequence ordering data-driven	Post-hoc selection	Pre-specify clinical priority in SAP
Bonferroni at 10 correlated endpoints	Default conservatism	Graphical procedure (gMCP); 30-50% power gain
FDR for confirmatory primary	Misunderstanding error rates	FWER mandatory for confirmatory; FDR exploratory only
Graphical procedure run with multiple weight schemes	Post-hoc graph tuning	Pre-specify single graph in SAP
Subgroups significant without multiplicity	Cherry-picking	Pre-specified allocation OR explicit hypothesis-generating label
Co-primary treated as multiple primary	Confused alpha allocation	Co-primary: no alpha split; inflate n. Multiple primary: split alpha
Win-ratio component priority unspecified	Data-driven choice	Pre-specify hierarchy with rationale; sensitivity over alternatives
multipletests default method='hs' (Holm-Sidak)	Common Python mistake	Always specify method='holm', 'hommel', etc., explicitly
Sensitivity analysis listed as a "key secondary" requiring alpha	Confusion about role	Sensitivity is "what if" not "another claim"; no alpha needed

Anticipated Reviewer Pushback

Pushback	Response
"Why this multiplicity procedure?"	Closed testing per Marcus-Peritz-Gabriel; specific implementation is graphical (Bretz-Maurer 2009) with pre-specified weights in SAP
"Why Hommel not Holm?"	PRDS holds (positive correlation among endpoints); Hommel dominates Holm by 1-3% with no Type-I cost
"Why graph weights X, Y, Z?"	Clinical priority: primary > key secondary > exploratory; weights reflect labelling claim hierarchy
"Are these endpoints positively correlated?"	Sensitivity analyses provided: Bonferroni, Holm, Hochberg, Hommel results all in CSR appendix; concordant
"Where is alpha for the subgroup analysis?"	Pre-specified 20% of primary alpha allocated (a common convention); cite Dane 2019 for subgroup discipline
"Why not just composite endpoint?"	Composite would dilute differential effect on mortality vs hospitalisation; key-secondary hierarchy preserves component-level claims
"PRDS check for Hochberg?"	Endpoints positively correlated via simulation under null; PRDS holds; Hochberg/Hommel valid
"Sensitivity in the hierarchy?"	No — sensitivity is "what if" and does not require alpha. Listed as supportive not key secondary.

References

• Bretz F, Maurer W, Brannath W, Posch M. 2009. A graphical approach to sequentially rejective multiple test procedures. Stat Med 28:586-604.
• Bretz F, Posch M, Glimm E, Klinglmueller F, Maurer W, Rohmeyer K. 2011. Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests. Biom J 53:894-913.
• Burman CF, Sonesson C, Guilbaud O. 2009. A recycling framework for the construction of Bonferroni-based multiple tests. Stat Med 28:739-761.
• Dmitrienko A, Offen WW, Westfall PH. 2003. Gatekeeping strategies for clinical trials that do not require all primary effects to be significant. Stat Med 22:2387-2400.
• Dmitrienko A, Tamhane AC, Wiens BL. 2008. General multistage gatekeeping procedures. Biom J 50:667-677.
• FDA. 2022. Multiple Endpoints in Clinical Trials. Final Guidance.
• Goeman JJ, Hemerik J, Solari A. 2021. Only closed testing procedures are admissible for controlling false discovery proportions. Ann Stat 49:1218-1238.
• Guilbaud O. 2007. Bonferroni parallel gatekeeping -- transparent generalizations, adjusted p-values, and short proofs. Biom J 49:917-927.
• Hochberg Y. 1988. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75:800-802.
• Holm S. 1979. A simple sequentially rejective multiple test procedure. Scand J Stat 6:65-70.
• Hommel G. 1988. A stagewise rejective multiple test procedure based on a modified Bonferroni test. Biometrika 75:383-386.
• Marcus R, Peritz E, Gabriel KR. 1976. On closed testing procedures with special reference to ordered analysis of variance. Biometrika 63:655-660.
• Maurer W, Bretz F. 2013. Memory and other properties of multiple test procedures generated by entangled graphs. Stat Med 32:1739-1753.
• Pocock SJ, Ariti CA, Collier TJ, Wang D. 2012. The win ratio: a new approach to the analysis of composite endpoints in clinical trials. Eur Heart J 33:176-182.
• Sarkar SK. 2008. Generalizing Simes' test and Hochberg's stepup procedure. Ann Stat 36:337-363.

Related Skills

• clinical-biostatistics/trial-reporting - Multiplicity strategy reporting per CONSORT 2025
• clinical-biostatistics/subgroup-analysis - Subgroup multiplicity allocation
• clinical-biostatistics/power-and-sample-size - Power adjustment for co-primary endpoints
• clinical-biostatistics/adaptive-designs - Combination tests for adaptive multiplicity
• clinical-biostatistics/effect-measures - Reporting multiple effect measures post-multiplicity adjustment
• experimental-design/multiple-testing - General methods (FDR, FWER, q-values)